Misuse of Drugs (Medicinal Cannabis) Amendment Bill

  • enacted
4 Section 2 amended (Interpretation)

(1)

In section 2(1), insert in its their appropriate alphabetical order:

CBD product means a product that—

(a)

contains cannabidiol; and

(b)

if it contains other cannabinoids usually found in cannabis, contains those cannabinoids in a quantity that, in total, constitutes no more than 2% of the total quantity of cannabinoids in the product; and

(c)

does not contain any other controlled drug; and

(d)

does not contain a psychoactive substance (as defined in section 9 of the Psychoactive Substances Act 2013)

terminal illness means an illness from which a person can reasonably be expected to die within 12 months

CBD product has the meaning given in section 2A

non-psychoactive THC analogue means a substance that—

(a)

occurs naturally in cannabis; and

(b)

is not capable of inducing more than a minor psychoactive effect, by any means, in a person; and

(c)

has a structure substantially similar to that of—

(i)

a tetrahydrocannabinol; or

(ii)

an isomer, ester, or ether of a tetrahydrocannabinol; or

(iii)

an ester or ether of an isomer of a tetrahydrocannabinol; or

(iv)

a salt of any substance described in subparagraphs (i) to (iii)

(2)

In section 2(1), definition of controlled drug analogue, after paragraph (c), insert:

(d)

a non-psychoactive THC analogue

(3)

After section 2(1A), insert:

(1B)

In this Act, a person requires palliation if, in the opinion of a medical practitioner or nurse practitioner, the person has an advanced progressive life-limiting condition and is nearing the end of their life.